Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -17.99M | -6.39M | 19.58M | 20.11M | 15.55M |
| Total Depreciation and Amortization | 2.06M | 1.92M | 1.70M | 1.48M | 1.36M |
| Total Amortization of Deferred Charges | 10.50K | 7.00K | 3.50K | -- | 3.50K |
| Total Other Non-Cash Items | 6.95M | -1.48M | -28.43M | -31.03M | -8.40M |
| Change in Net Operating Assets | 14.56M | 10.21M | 9.72M | 6.17M | -10.88M |
| Cash from Operations | 5.60M | 4.27M | 2.58M | -3.27M | -2.37M |
| Capital Expenditure | -1.27M | -1.68M | -1.59M | -809.60K | -942.20K |
| Sale of Property, Plant, and Equipment | 125.30K | 125.30K | 15.30K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -900.00K | -900.00K | -900.00K | -- | -- |
| Cash from Investing | -2.05M | -2.46M | -2.47M | -809.60K | -942.20K |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 4.00M | 3.89M |
| Total Debt Repaid | -1.09M | -934.20K | -793.00K | -660.90K | -12.65M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 39.50K | 39.50K | 39.50K | 39.50K | -- |
| Cash from Financing | -1.05M | -894.60K | -753.40K | 3.38M | -8.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.50M | 922.50K | -646.60K | -705.50K | -12.07M |